Loading
Latest filing published 06 Jul 2021 for MEI Pharma, Inc., €103k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Daniel P. Gold PhD (chief executive) discloses dealings in 2 companies, chiefly MMRGlobal, Inc. and Lite Strategy, Inc. We count 19 filings; the first trade dates from 12 December 2006 and the latest from 2 July 2021.
Purchases make up the whole of the open-market record (1 purchase, €27k). Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 5 share grants and 3 option exercises.
The newest entry dates from 6 July 2021: a share grant of €103k, in Lite Strategy, Inc. The last purchase on record was published on 20 December 2019, which is 2,500 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations